Rhea, a global leader in reproductive health services, is proud to introduce GenPrime, its cutting-edge fertility service platform, as part of a comprehensive end-to-end reproductive health ecosystem. GenPrime is designed to streamline the fertility journey for modern families, offering a global network of owned and partner clinics, all integrated with Rhea’s advanced technology platform, Rhea Labs.
GenPrime is at the heart of Rhea’s mission to connect prospective families across Asia, North America, and Europe, helping to eliminate barriers in the fragmented fertility services market. This patient-focused platform enhances the fertility experience by providing robust patient journey management tools, integrated with Rhea Labs for continuous innovation and improved patient outcomes.
Following its latest funding round, led by Thiel Capital, and the acquisition of Embryonics, a leader in AI-driven fertility technologies, Rhea is poised for continued global expansion. Through strategic partnerships, like the one with Baylor College of Medicine, Rhea is advancing reproductive health with initiatives such as RheaX, a global gamete exchange platform aimed at improving gamete matching and transfers.
With the appointment of Margaret Wang as CEO in 2023, Rhea is set to reshape the landscape of reproductive health services, making fertility care more accessible and effective than ever before. Headquartered in Singapore and New York, the company is expanding its services to new regions, ensuring that families around the world have the tools and support they need to navigate their fertility journeys.
Read the original article here